SEC filing record
Primary Source · SEC.gov

Cytogel Pharma, LLC

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalFirst saleForm D/A · 2025-12-237 events: 2 investors increased, 2 sold increased, 1 first saleLast filing 2025-12-23

Raised

Pre-open

Investors

—

Min Invest

$50,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Cytogel Pharma, LLC is a Connecticut limited liability company that first filed a Form D on March 20, 2014 and most recently amended it on March 26, 2026 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. Cytogel Pharma, LLC reported that the first sale had not yet occurred as of the Form D filed March 26, 2026, so no amount sold or investor count is on file. The total offering amount is $16,000,000. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000. The Form D names FDX Capital LLC (CRD 000119302), associated with None; XMS Capital Partners, LLC (CRD 000142871), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $1,120,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 3 Thorndal Circle, Darien, CT 06820.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001491841
Entity NameCytogel Pharma, LLC
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeLimited Liability Company
Jurisdiction of OrganizationConnecticut
Issuer Address3 Thorndal Circle, Darien, CT 06820
Phone(203) 966-9867
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateNot yet occurred (as filed)
Filing DateMarch 26, 2026
Accession Number0001213900-26-034790
Total Offering Amount$16,000,000
Total Amount Sold$0 (no sales yet)
Amount Remaining$16,000,000
Total Investors0 (no sales yet)
Non-Accredited InvestorsNone
Minimum Investment$50,000
Offering DurationOne year or less
Sales Commissions$1,120,000 (to FDX Capital LLC and 1 other)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)CT
Amendment Count14 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

7

latest Dec 23, 2025

Critical / warning

0 / 1

0 watch · 6 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

6

lapsed, dark, pre_sale

Latest event New filer · Dec 23, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 7 filing events with values and deltas, latest 2025-12-23, and alerts on the next one
  • 6 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

C. Dean Maglaris

Executive Officer, Director · New Canaan, CT

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Jerry P. Leamon

Director · Cos Cob, CT

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Cassandra P. Klimp

Director · Southport, CT

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Frederick W. Telling

Executive Officer, Director · Port Orange, FL

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Steven W. Chrust

Director · Brooklyn, NY

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Michael W. Ullmann

Director · Princeton, NJ

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Eric W. Lang

Director · Plainsboro, NJ

"The issuer is an LLC; the ""director"" function is fulfilled by Managers."

Theodore W. Maione

Executive Officer · Troy, NY

Dr. Maione is the Issuer's Chief Scientific Officer.

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

FDX Capital LLCCRD 000119302 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

XMS Capital Partners, LLCCRD 000142871 on BrokerCheck

Associated broker-dealer: None · Chicago, IL · Soliciting in all states

Questions About Cytogel Pharma, LLC

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Cytogel Pharma, LLC?

Cytogel Pharma, LLC is a Connecticut limited liability company that filed a Form D with the SEC on March 26, 2026 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is Cytogel Pharma, LLC legit?

AltStreet does not rate legitimacy; it reports the public record. Cytogel Pharma, LLC filed a Form D with the SEC on March 26, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Cytogel Pharma, LLC registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Cytogel Pharma, LLC claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Cytogel Pharma, LLC raised?

Cytogel Pharma, LLC reported that the first sale had not yet occurred as of the Form D filed March 26, 2026, so no amount sold or investor count is on file. The total offering amount is $16,000,000.

Who can invest in Cytogel Pharma, LLC?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000.

What is the minimum investment in Cytogel Pharma, LLC?

The Form D lists $50,000 as the minimum investment accepted from any outside investor as of March 26, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Cytogel Pharma, LLC and how are they paid?

The Form D names FDX Capital LLC (CRD 000119302), associated with None; XMS Capital Partners, LLC (CRD 000142871), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $1,120,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Cytogel Pharma, LLC?

The Form D lists 8 related persons: C. Dean Maglaris, executive officer, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Jerry P. Leamon, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Cassandra P. Klimp, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Frederick W. Telling, executive officer, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Steven W. Chrust, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Michael W. Ullmann, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Eric W. Lang, director ("The issuer is an LLC; the ""director"" function is fulfilled by Managers."); Theodore W. Maione, executive officer (Dr. Maione is the Issuer's Chief Scientific Officer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Cytogel Pharma, LLC located?

The issuer's address on its SEC filings is 3 Thorndal Circle, Darien, CT 06820. Its phone number of record is 203-966-9867. It is organized under the laws of Connecticut.

How long is the Cytogel Pharma, LLC offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 6 amendments are on record for this CIK.

What is Cytogel Pharma, LLC's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.